News

Executively Speaking click-newsletter

It’s been incredibly busy for us here at FHA and with the year winding down, I want to take a minute to thank all of our supporters, volunteers and donors that were instrumental in helping us achieve our goals and for providing their assistance to make our programs, events and various outings a success. With that said, we’ve already got a head start on 2015 as we have several new things up our sleeve. Please stay connected by checking out the website and our
Facebook page for up-to-date information.

One of our main focuses in 2014 was the launch of the Bleeding Disorder Coalition of Florida (BDCF). The coalition hosted its first State Advocacy Day on March 20, 2014 at our State Capitol, which proved to be very successful with over 20 scheduled visits with Florida legislators and staff. BDCF and its volunteers will continue to develop an important dialogue with the key Florida decision makers. If you have a passion for advocacy and are interested in getting involved, please contact us at info@floridahemophilia.org

Finally, we are always looking for volunteers to serve on the following committees: 5th Annual Walk in the Jungle and the 32nd Annual Family Education Symposium. If you are interested or have some ideas that you’d like to share, please contact me directly at dadamkin@floridahemophilia.org

I look forward to seeing you in 2015!
Debbi Adamkin
FHA Executive Director

Informe Ejecutivo

Este año ha sido increíblemente movido para nosotros aquí en la FHA y como ya va a finalizarse, quiero tomar un momento para agradecerles a todos nuestros partidarios, voluntarios y donantes que fueron instrumentales para ayudarnos a alcanzar nuestros objetivos y por proporcionar su asistencia y hacer que nuestros programas, eventos y diversas salidas fueran un éxito. Dicho esto, ya tenemos una ventaja en2015 ya que tenemos varias cosas nuevas planeadas. Por favor, manténganse informados de nuestra página web y nuestra página de Facebook para obtener la información mas actualizada.

En el 2014 el enfoque principal fue el lanzamiento de la Coalición de Enfermedades Sanguíneas de la Florida (Bleeding Disorder Coalition of Florida, BDCF). La coalición organizó su primera Día de Abogacía Estatal el 20 de marzo de 2014 en nuestro Capitolio de la Florida el cual resultó ser un gran éxito con más de 20 citas con los legisladores y el personal de la Florida. BDCF y sus voluntarios continuation desarrollando un diálogo importante con personas claves al hacer decisiones en la Florida. Si usted es apasionado por la abogacía y está interesado en participar, por favor póngase en contacto con nosotros en info@floridahemophilia.org

Por último, siempre estamos buscando voluntarios para servir en los siguientes comité: 5ta Caminata Anual en la Selva y el Simposio 32 Anual de Educación Familiar. Si usted está interesado o tiene algunas ideas que le gustaría compartir, por favor póngase en contacto conmigo directamente en dadamkin@floridahemophilia.org

Debbi Adamkin
Directora Ejecutiva de FHA

 

 

Product News

Grifols launches new 2000 FVIII IU ALPHANATE® (Antihemophilic Factor/von Willebrand Factor Complex [Human]) assay

 

Grifols, a leader in the production of plasma-derived medicines, announces the launch of a 2000 IU/vial assay size for ALPHANATE.  ALPHANATE is indicated for the control and prevention of bleeding in patients with Hemophilia A and for surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease in whom desmopressin (DDAVP) is either ineffective or contraindicated.  It is not indicated for patients with sever VWD (Type 3) undergoing major surgery.

 

With the launch of the new 2000 IU FVIII ALPHANATE assay, Grifols will now supply the largest FVIII and von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) assay available on the market for any plasma-derived FVIII concentrate. The higher potency allows patients who previously used a 1500 IU assay to reduce their potential total administration time by 30% every day.

 

“This higher potency offers a significant advantage to Hemophilia A patients that require high dose therapy,” said Joel Abelson, President of North American Commercial Operations. “Since the approval of the 2000 IU FVIII assay, ALPHANATE has twice the factor and half the volume of any other FVIII/VWF complex product. The larger assay may help patients decrease their overall infusion time and will reduce the total volume needed for a high dose infusion.”

 

The 2000 IU FVIII ALPHANATE assay will be available October 1, 2014.